ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Milliman releases 2025 report on U.S. organ and tissue transplant costs, utilization, and emerging issues

Estimated annual per member per month organ transplant costs rise 5.2% (age 65 or less) and 9.1% (ages 65+) since 2020

Milliman, Inc., a premier global actuarial consulting, risk management, and technology firm, today released its 2025 report on U.S. organ and tissue transplant costs and utilization. This comprehensive study provides valuable insight into the financial landscape and emerging trends in transplant care, including estimated transplants, lengths of hospital stay, and average annual costs per member per month (PMPM) across single organ/tissue and double-organ/tissue transplants.

The study found that for all combined organ and tissue transplants, per member costs based on billed charges saw an average annual increase of 5.2% for those under age 65, and 9.1% for those age 65 and over when compared to the 2020 report.

Among single organ or tissue transplants, double-lung transplants have the highest billed charges in the U.S., at an estimated $2.3 million dollars, followed by heart transplant ($1.9 million), single lung ($1.8 million) and intestine ($1.7 million). In terms of utilization, the study estimates over 28,000 kidney transplants will be performed in 2025 – by far the most of any organ – followed by nearly 11,000 liver transplants.

"A number of emerging issues and innovations in the transplant space, including benchmarking, fair distribution and availability of organs and tissue, living donation and bioengineering, and artificial intelligence have our attention,” said Nick Ortner, a senior consulting actuary with Milliman and co-author of the study. “Understanding costs, utilization, and the impact of new technologies can enable the healthcare industry – and consumers – to better navigate the complexities of transplant care and work toward more effective solutions.”

To read the full report, visit: https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization

About Milliman

Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at milliman.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.